# Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis

> **NCT07565701** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Geoff Block** · enrollment: 100 (estimated)

## Conditions studied

- Anemia Associated With Chronic Kidney Disease

## Interventions

- **DRUG:** Epoetin alga (Epogen)/vadadustat

## Key facts

- **NCT ID:** NCT07565701
- **Lead sponsor:** Geoff Block
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-04
- **Final completion:** 2027-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07565701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07565701, "Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07565701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*